Sunitinib-Induced Elevation of Mean Corpuscular Volume (MCV)-Exploring Its Possible Clinical Relevance in Cancer Patients

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F22%3A00076164" target="_blank" >RIV/00159816:_____/22:00076164 - isvavai.cz</a>

Alternative codes found

RIV/65269705:_____/22:00076164 RIV/00209805:_____/22:00079016 RIV/00216224:14110/22:00125957

Result on the web

<a href="https://www.mdpi.com/1718-7729/29/6/330" target="_blank" >https://www.mdpi.com/1718-7729/29/6/330</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3390/curroncol29060330" target="_blank" >10.3390/curroncol29060330</a>

Result language

angličtina

Original language name

Sunitinib-Induced Elevation of Mean Corpuscular Volume (MCV)-Exploring Its Possible Clinical Relevance in Cancer Patients

Original language description

Sunitinib is a broad-spectrum multitargeted tyrosine kinase inhibitor mainly used as second-line therapy for non-resectable gastrointestinal stromal or first-line treatment option of metastatic renal cell carcinoma (mRCC), and as an &quot;off-label&quot; option in pediatric oncology. It has been previously reported that sunitinib elevates the mean corpuscular volume of erythrocytes (MCV) in treated subjects. The aim of this study was to assess time-dependent changes of this effect and evaluate its possible clinical relevance. In this study, 179 adult and 21 pediatric patients with solid tumors treated with sunitinib were retrospectively analyzed. The laboratory and treatment-related data were collected for each treatment period. The regression model with a broken-line relationship was used to fit time dependence of the MCV. In the adult group, the MCV was increasing during the first 21.6 weeks (median) of treatment in a median level of 99.8 fL, where it stabilized. MCV increase was faster in the patients who suffered from treatment-related adverse events (21.3 vs. 24.6 weeks, p = 0.010). In the pediatric cohort, the MCV dynamics were similar to adults. In conclusion, MCV changes during sunitinib treatment in pediatric and adult patients may be of clinical utility in monitoring sunitinib treatment course.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30204 - Oncology

Project

Result was created during the realization of more than one project. More information in the Projects tab.

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2022

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Current Oncology

ISSN

1198-0052

e-ISSN

1718-7729

Volume of the periodical

29

Issue of the periodical within the volume

6

Country of publishing house

CA - CANADA

Number of pages

10

Pages from-to

4138-4147

UT code for WoS article

000816104700001

EID of the result in the Scopus database

—